These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30899264)

  • 1. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
    Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
    Front Immunol; 2019; 10():390. PubMed ID: 30899264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.
    Hargreaves CE; Iriyama C; Rose-Zerilli MJ; Nagelkerke SQ; Hussain K; Ganderton R; Lee C; Machado LR; Hollox EJ; Parker H; Latham KV; Kuijpers TW; Potter KN; Coupland SE; Davies A; Stackpole M; Oates M; Pettitt AR; Glennie MJ; Cragg MS; Strefford JC
    PLoS One; 2015; 10(11):e0142379. PubMed ID: 26545243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
    Robinson JI; Md Yusof MY; Davies V; Wild D; Morgan M; Taylor JC; El-Sherbiny Y; Morris DL; Liu L; Rawstron AC; Buch MH; Plant D; Cordell HJ; Isaacs JD; Bruce IN; Emery P; Barton A; Vyse TJ; Barrett JH; Vital EM; Morgan AW; ;
    EBioMedicine; 2022 Dec; 86():104343. PubMed ID: 36371989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
    López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
    Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.
    Paul P; Pedini P; Lyonnet L; Di Cristofaro J; Loundou A; Pelardy M; Basire A; Dignat-George F; Chiaroni J; Thomas P; Reynaud-Gaubert M; Picard C
    Front Immunol; 2019; 10():1208. PubMed ID: 31249568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.
    Alakhras NS; Qiu J; Rocha GV; Witcher DR; Koester A; You J; Schaer DA; Holmgaard RB; Driscoll K; Willy JA; Malherbe LP
    MAbs; 2018; 10(6):913-921. PubMed ID: 29953319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant.
    Phaahla NG; Lassaunière R; Da Costa Dias B; Waja Z; Martinson NA; Tiemessen CT
    Front Immunol; 2019; 10():735. PubMed ID: 31024562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
    Hurvitz SA; Betting DJ; Stern HM; Quinaux E; Stinson J; Seshagiri S; Zhao Y; Buyse M; Mackey J; Driga A; Damaraju S; Sliwkowski MX; Robert NJ; Valero V; Crown J; Falkson C; Brufsky A; Pienkowski T; Eiermann W; Martin M; Bee V; Marathe O; Slamon DJ; Timmerman JM
    Clin Cancer Res; 2012 Jun; 18(12):3478-86. PubMed ID: 22504044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
    Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
    J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly sensitive
    Ito S; Miwa K; Hattori C; Aida T; Tsuchiya Y; Mori K
    J Immunotoxicol; 2021 Dec; 18(1):136-143. PubMed ID: 34644231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptors.
    Mold C; Du Clos TW
    J Immunol; 2006 Jun; 176(12):7598-604. PubMed ID: 16751406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Fc-γ Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation.
    Sakai H; Tanaka Y; Tazawa H; Shimizu S; Verma S; Ohira M; Tahara H; Ide K; Ishiyama K; Kobayashi T; Onoe T; Ohdan H
    Transplant Direct; 2017 Jun; 3(6):e164. PubMed ID: 28620648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
    Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
    mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
    Wing MG; Moreau T; Greenwood J; Smith RM; Hale G; Isaacs J; Waldmann H; Lachmann PJ; Compston A
    J Clin Invest; 1996 Dec; 98(12):2819-26. PubMed ID: 8981930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cell-based assay for predictively evaluating the FcγR-mediated human immune cell activation by therapeutic monoclonal antibodies.
    Takakura M; Tada M; Ishii-Watabe A
    Biochem Biophys Res Commun; 2017 Mar; 485(1):189-194. PubMed ID: 28196745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.